- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 57
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1584
of 6,454
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- carfilzomib, belatacept, Bone marrow aspiration
- Biological · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hyperkalemia, Heart Failure
- Interventions
- patiromer, placebo
- Drug
- Lead sponsor
- Relypsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 9
- States / cities
- Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
- Conditions
- End Stage Renal Disease, Transplantation
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 7,029 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Kidney Failure, Chronic, Renal Dialysis
- Interventions
- InnAVasc arteriovenous graft surgical implant
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- San Diego, California • Flint, Michigan • Greenwood, Mississippi + 4 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Bevacizumab, Ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Charleston, South Carolina
- Conditions
- Anemia
- Interventions
- ferumoxytol or oral iron
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tempe, Arizona • New Haven, Connecticut + 10 more
- Conditions
- Chronic Kidney Disease
- Interventions
- SBR759
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F
- Interventions
- AGS-16M8F
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Seattle, Washington
- Conditions
- Sickle Cell Disease, Kidney Diseases, Chronic
- Interventions
- Biospecimen/DNA collection and analysis
- Other
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee
- Conditions
- Kidney, Polycystic, Autosomal Dominant
- Interventions
- Water
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anaemia
- Interventions
- Daprodustat (GSK1278863), Placebo, Iron therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 49
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more
- Conditions
- Lupus Nephritis
- Interventions
- VIB4920, Placebo for VIB4920
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Kidney Failure, Chronic
- Interventions
- growth hormone
- Drug
- Lead sponsor
- FDA Office of Orphan Products Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Kidney Transplant
- Interventions
- Mycophenolate Mofetil (CellCept), Dietary Monitoring, Drug Diary, Blood Sampling
- Drug · Behavioral · Procedure
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Renal Cell Carcinoma, Urinary Bladder Neoplasms
- Interventions
- Pembrolizumab, Vorinostat
- Drug
- Lead sponsor
- Nabil Adra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
- Interventions
- 177Lu-J591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertensive Renal Disease
- Interventions
- USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
- Behavioral · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
- Interventions
- Fostamatinib disodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tumor
- Interventions
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • Fort Wayne, Indiana
- Conditions
- Cancer of Skin, Cancer of Kidney, Cancer of Bladder, Exercise, Aerobic, Immunotherapy
- Interventions
- Pedaling Group
- Behavioral
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Utilization, Health Care, Obesity
- Interventions
- Caregivers, Non-caregivers
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Bacterial Infections
- Interventions
- Xeruborbactam Oral Prodrug, Ceftibuten
- Drug
- Lead sponsor
- Qpex Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Biological · Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina